Chronic Intestinal Pseudo-obstruction Clinical Trial
Official title:
Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 Trial
Verified date | June 2021 |
Source | Yokohama City University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of the study is to investigate efficacy and safety of rifaximin (L-105) in patients with chronic idiopathic intestinal pseudo-obstruction(CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma
Status | Active, not recruiting |
Enrollment | 12 |
Est. completion date | January 2022 |
Est. primary completion date | November 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 74 Years |
Eligibility | Inclusion Criteria: - Outpatients aged =20 and <75 on the day of informed consent (IC) - Patients with CIIPO (designated intractable disease 99) at enrollment, satisfying all the criteria specified in (1) to (7) of the CIIPO Diagnostic Criteria issued in 2014 by the MHLW Research Group, or patients with CIPO, secondary to systemic scleroderma, satisfying all the same criteria specified in (1) to (6) - Patients' levels of abdominal bloating symptoms, 4 scales of GSS, should be score 2 or 3 at the time of IC acquisition and enrollment. Exclusion Criteria: - Patients with malignant diseases (excluding those whose symptoms are stable and who do not require aggressive treatments such as chemotherapy and/or surgical therapy) - Patients with psychiatric diseases (excluding those whose symptoms are stable, and the investigator or coinvestigator concludes that efficacy of the patient can be assessed without any issue) - Patients with severe diabetes within 5 weeks before enrollment (HbA1c >10%) - Patients who have already had gastrostomy (including percutaneousendoscopic gastro -jejunostomy, PEG-J), enterostomy, or colostomy - Patients who underwent intestinal decompression therapy not associated with surgical procedures (trans-nasal ileus tube) within 4weeks before enrollment - Patients who used antimicrobials, antiparasitics or antifungals (excluding topical use) within 4 weeks before enrollment - Patients who have changed the doses of the following concomitantly administered drugs within 4 weeks before enrollment: mosapride, daikenchuto, metoclopramide, acotiamide - Patients with severe hepatic disorders within 5 weeks before enrollment (who meet either one of the following criteria: AST= 5 x the upper limit of the common reference value specified in the Japanese Committee for Clinical Laboratory Standards (JCCLS), ALT= 5 x the upper limit of the common reference value specified in JCCLS, total bilirubin = 3 x the upper limit of the common reference value specified in JCCLS, decompensated hematic cirrhosis, or jaundice) - Patients who are pregnant, breastfeeding, possibly pregnant, or those who wish to become pregnant - Patients with a previous history of hypersensitivity to any investigational product ingredients - Patients with active tuberculosis - Patients who participated in other clinical trial (including a trial with an investigational product) within 12 weeks before this enrollment and who received an intervention with a test drug - Other patients whose participation in the trial is concluded to be inappropriate by the investigator or coinvestigator |
Country | Name | City | State |
---|---|---|---|
Japan | Yokohama city university | Yokohama | Kanagawa |
Lead Sponsor | Collaborator |
---|---|
Yokohama City University | ASKA Pharmaceutical Co., Ltd. |
Japan,
Ohkubo H, Iida H, Takahashi H, Yamada E, Sakai E, Higurashi T, Sekino Y, Endo H, Sakamoto Y, Inamori M, Sato H, Fujimoto K, Nakajima A. An epidemiologic survey of chronic intestinal pseudo-obstruction and evaluation of the newly proposed diagnostic criteria. Digestion. 2012;86(1):12-9. doi: 10.1159/000337528. Epub 2012 Jun 15. — View Citation
Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M, Savarino E, Indiveri F, Savarino V, Ghio M. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol. 2008 May;103(5):1257-62. doi: 10.1111/j.1572-0241.2007.01758.x. Epub 2008 Apr 16. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Small intestinal bacterial overgrowth (SIBO) in a glucose-hydrogen breath test | Elimination rate of SIBO in a glucose-hydrogen breath test | Before, 4 weeks after administration;and 8 weeks after the end of administration | |
Other | Changes of Serum endotoxin activity | Serum endotoxin activity, ranging from 0.00-1.00, is assessed using EAA® (endotoxin activity assay, Toray Medical Co., Ltd.), FDA approved rapid whole blood assay for detection of human endotoxemia. 0.00-0.39 means low level, 0.40-0.59 means middle level, and =0.60 means high level. | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Other | Fecal test (intestinal flora) | Changes of intestinal flora detected by 16SrDNA amplicon analysis using next generation sequencing. | Before and 4 weeks after administration | |
Other | Adverse events | Incidence of adverse events | From the start of administration to 8 weeks after the end of administration | |
Other | Changes from baseline of hematological parameters | Hematological parameters (red blood cell count, hematocrit, white blood cell count, platelet count) are calculated for safety assessment | Before, 2 and 4 weeks after administration; and 4 and 8 weeks after the end of administration | |
Other | Changes from the baseline of total protein | Total protein is calculated for safety assessment | Before, 2 and 4 weeks after administration; and 4 and 8 weeks after the end of administration | |
Other | Changes from the baseline of liver function | Liver function parameters (aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, total bilirubin) are calculated for safety assessment. | Before, 2 and 4 weeks after administration; and 4 and 8 weeks after the end of administration | |
Other | Changes from the baseline of renal function | Creatinine and blood urea nitrogen are calculated for safety assessment. | Before, 2 and 4 weeks after administration; and 4 and 8 weeks after the end of administration | |
Other | Changes from the baseline of electrolytes | Electrolytes (sodium, potassium, chlorine, calcium) are calculated for safety assessment. | Before, 2 and 4 weeks after administration; and 4 and 8 weeks after the end of administration | |
Other | Changes from the baseline of blood lipid level | Blood lipid level (total cholesterol, triglyceride, and high-density lipoprotein cholesterol) is calculated for safety assessment. | Before, 2 and 4 weeks after administration; and 4 and 8 weeks after the end of administration | |
Other | Changes from the baseline of C reactive protein | C reactive protein is calculated for safety assessment. | Before, 2 and 4 weeks after administration; and 4 and 8 weeks after the end of administration | |
Other | Changes from the baseline of serum glucose level | Serum glucose level is calculated for safety assessment. | Before, 2 and 4 weeks after administration; and 4 and 8 weeks after the end of administration | |
Primary | Improvement ratio (%) in abdominal bloating score in Global Symptomatic Score (GSS) | Abdominal bloating score in Global Symptomatic Score (GSS) is used. GSS is a 4-point Likert scale ranging from 0 (no symptom) to 3 (severe, incapacitating with inability to perform normal activities), with lower scores reflecting better symptoms. Score 0 or 1 is defined as improvement. | at the end of administration (4 weeks) | |
Primary | Improvement ratio (%) in Gastrointestinal (GI) symptoms score | Gastrointestinal score (GI score) is a 5-point Likert scale (0; greatly improved, 1; improved, 2; no change, 3; worsened, 4; severely worsened), with lower scores reflecting more improved symptoms. Score 0 or 1 is defined as improvement. | at the end of administration (4 weeks) | |
Secondary | Changes of the improvement ratio (%) in abdominal bloating score | Abdominal bloating score in Global Symptomatic Score (GSS) is used. GSS is a 4-point likert scale ranging from 0 (no symptom) to 3 (severe, incapacitating with inability to perform normal activities), with lower scores reflecting better symptoms. Score 0 or 1 is defined as improvement. | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes of abdominal bloating score | Abdominal bloating score in Global Symptomatic Score (GSS) is used. GSS is a 4-point likert scale ranging from 0 (no symptom) to 3 (severe, incapacitating with inability to perform normal activities), with lower scores reflecting better symptoms. | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes of the improvement ratio (%) in gastrointestinal symptoms score | Gastrointestinal score (GI score), a 5-point likert scale (0; greatly improved, 1; improved, 2; no change, 3; worsened, 4; severely worsened), with lower scores reflecting more improved symptoms, is used. Score 0 or 1 is defined as improvement. | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes of the "good" ratio (%) in gastrointestinal symptoms score | Gastrointestinal score (GI score), 5-point likert scale (0; very good, 1; good, 2; average, 3; bad, 4; extremely bad), with lower scores reflecting better conditions, is used. Score 0 or 1 is defined as ''good''. | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes of each score in Global Symptomatic Score other than abdominal bloating score | Global Symptomatic Score (GSS), a 4-point likert scale ranging from 0 (no symptom) to 3 (severe), of the following symptoms are assessed; (a. diarrhea, b. epigastric pain/ discomfort, c. pain in the lower quadrant/discomfort, d. tenderness, e. nausea, f. vomiting). | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes of total scores in Global Symptomatic Score | Sum of Global Symptomatic Score (GSS) of the following 7 symptoms, 0 to maximum of 21, are assessed; (a. diarrhea, b. epigastric pain/discomfort, c. abdominal distention, d. pain in the lower quadrant/discomfort, e. tenderness, f. nausea, g. vomiting). | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes of the improvement ratio (%) in General health condition (symptoms) score | General health condition (symptoms) score, a 5-point likert scale (0; greatly improved, 1; improved, 2; no change, 3; worsened, 4; severely worsened), with lower scores reflecting more improved symptoms, is used. Score 0 or 1 is defined as improvement. | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes of the "good" ratio (%) in General health condition (symptoms) score | General health condition (symptoms) score, 5-point scale (0; very good, 1; good, 2; average, 3; bad, 4; extremely bad), with lower scores reflecting better conditions, is used. Score 0 or 1 is defined as ''good''. | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Patient satisfaction score | % of the "satisfaction" ratio in patient satisfaction score | At the end of the administration (4 weeks) | |
Secondary | Changes of Short Form (SF)-8 health survey score | SF-8(short form-8), a self-reporting health survey ranging from 8 to maximum of 42, with lower scores reflecting better conditions, is used. | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Small intestinal volume measured by abdominal CT scan | Changes of small intestinal volume measured by abdominal CT scan | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes from baseline of serum albumin level | Serum albumin level is calculated for nutritional assessment | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes from baseline of prealbumin (transthyretin) | Prealbumin (transthyretin) is calculated for nutritional assessment | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes from baseline of cholinesterase | Cholinesterase is calculated for nutritional assessment | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes from baseline of folic acid | Folic acid is calculated for nutritional assessment | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes from baseline of vitamin B12 (cobalamin) | Vitamin B12 (cobalamin) is calculated for nutritional assessment | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration | |
Secondary | Changes from baseline of serum iron | Serum iron is calculated for nutritional assessment | Before, 2 and 4 weeks after administration;and 4 and 8 weeks after the end of administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04506593 -
Indiana University Gastrointestinal Motility Diagnosis Registry
|
||
Recruiting |
NCT04193735 -
Pseudo-obstruction Assessment With MRI
|
||
Active, not recruiting |
NCT05724069 -
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
|
Phase 2 | |
Completed |
NCT00793247 -
Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)
|
Phase 2 |